The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
|Articles|November 1, 2022
Supplements and Featured Publications
- Biosimilars for Immune-Mediated Inflammatory Diseases: 2022 Update
- Volume 28
- Issue 12
Biosimilar medicines: what are they and how are they used?
Plain Language Summary
Advertisement
Plain Language Summary
Click the image to open in a new window.
Articles in this issue
Advertisement
Related to this article
In this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives demand for unregulated peptides.
Oncology leaders say clinical pathways must shift from static documents to tools that use patient-reported outcomes and AI to guide care.
SCOUT-HCM 56-week data show sustained LVOT gradient reductions with mavacamten and no LVEF below 50% in adolescents with obstructive HCM.
New analyses from VESALIUS-CV and the FOURIER open-label extension add stroke and long-term outcome data for evolocumab.
First-line IVF produced more live births than IUI within 7 months in couples with unexplained infertility.
Elafibranor and seladelpar normalized ALP in most patients with primary biliary cholangitis whose ALP was below the usual escalation threshold.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Advertisement
Advertisement
Trending on AJMC
1
Survodutide Meets CV Safety End Point in SYNCHRONIZE-CVOT
2
Pharmacy, Claims Data Show High Resmetirom Persistence in MASH
3
FDA Approves First Dual-Targeted Therapy for Advanced HNSCC
4
Phase 3 Data Back ALP Normalization as Treatment Goal in PBC
5